Table 4.
Ongoing and Completed Clinical Trials Employing Physical Methods for Gene Delivery
| ClinicalTrials.gov Identifier | Physical Methods | Cargo Type | Target Cells | Start Year | Aim |
|---|---|---|---|---|---|
| NCT00684294 | Electroporation | plasmid DNA | Tumor cells | 2008 | Tumor cell vaccine for advanced cancer |
| NCT01530698 | Electroporation | mRNA | Dendritic cells | 2010 | Dendritic cell vaccine for melanoma |
| NCT00968760 | Electroporation | plasmid DNA | T cells | 2011 | T cell immunotherapy for B lymphoma |
| NCT01456104 | Electroporation | mRNA | Dendritic cells | 2011 | Dendritic cell vaccine for melanoma |
| NCT02315118 | Electroporation | mRNA | T cells | 2014 | T cell immunotherapy for B lymphoma |
| NCT01995708 | Electroporation | mRNA | Dendritic cells | 2014 | Dendritic cell vaccine for multiple myeloma |
| NCT02117518 | Electroporation | mRNA | T cells | 2014 | Immunotargeting of reactive T cells which induces Type 1 Diabetes |
| NCT03083054 | Electroporation | mRNA | Dendritic cells | 2016 | Dendritic cell vaccine to suppress leukemia progression |
| NCT03166878 | Electroporation | mRNA | T cells | 2017 | Universal CAR-T cell for B lymphoma |
| NCT03415100 | Electroporation | mRNA | Natural killer cells | 2018 | Enhancing cell therapy specificity and activity for metastatic solid tumors |
| NCT03399448 | Electroporation | RNP | T cells | 2018 | Enhancing immune activity of the T cells toward refractory cancer |
| NCT04084951 | Mechanical | Protein | PBMC | 2020 | Enhancing immune response against tumor cells expressing HPV16 E6 and E7 |